Quiero saber acerca de...

lotter on DSK11XQN23PROD with NOTICES1

Federal Register / Vol. 86, No. 158 / Thursday, August 19, 2021 / Notices in control versus Tghs:miR-101a-sp hearts in Figure 4J of Development 2015
differences in 1 the amount of scarring, as represented by comparing AFOG staining in control and Tghs:miR-101a-sp and Tghs:miR133a1-pre hearts exposed to long term heat therapy in Figures 5A, 5B
and 5C, or Tropomyosin staining in Figures 5D, 5E, and 5F; and 2 the quantification of the scarring indices, tropomyosin expression, and injury area in Figures 5G, 5H, and 5I of Development 2015
increased Fosab expression in Tghs:miR-101a-sp ventricles relative to controls in Figures 6A and 6B, RNA
in situ hybridization studies in control and regenerating hearts detecting miR-101a expression in Figures 6C, 6D, 6E, and 6E, and Fosab expression in Figures 6F, 6G, 6H, and 6H of Development 2015
images reporting significant differences in Dsred expression, cardiomyocyte proliferation, collagen and fibrin staining, and scar tissue removal in ventricles from zebrafish treated with lna-Let-7, as compared to scrambled control, to support the importance of miR-101a in scar tissue removal/ventricular regeneration in Figures 6H, 6I, 6J, 7C, 7D, and 7E of Development 2015
reporting research methods and statistics that were not performed in the following experimental results:
PCR data in the graph represented in Figure 2B of PNAS 2018 draft, iScience 2018 draft, and iScience 2019, by representing the data from two 2 remote PCR experiments as being from the same experiment PCR data in the graph represented in Figure 2B of iScience Correction by reusing and relabeling a graph containing data that were the result of different experimental conditions exposure to heat shock, to include scrambled control data control data and statistical differences between control and experimental data represented in PNAS 2018 draft, iScience 2018 draft, iScience 2019, and iScience Correction, by falsely reporting the use of both antisense scrambled and LNA oligonucleotides that were designed and administered to adult animals via intraperitoneal injection at 10ug/g body weight representing the n of one biological replicate or one experiment as being multiple independent samples or experiments in iScience 2019 and iScience Correction control data and statistical differences between control and experimental
VerDate Sep<11>2014

17:28 Aug 18, 2021

Jkt 253001

data and the reported methods in Development 2015, concluding that miR-101a controls both CM
proliferation and scar tissue removal, by falsely reporting the use of LNA
oligonucleotides to modulate miR-101
activity in vivo to elucidate its contributions during adult heart regeneration Dr. Yin entered into a Voluntary Settlement Agreement Agreement and voluntarily agreed to the following:
1 Respondent agreed to have his research supervised for a period of two 2 years beginning on August 2, 2021.
Respondent agreed that prior to submission of an application for PHS
support for a research project on which Respondents participation is proposed and prior to Respondents participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondents duties is submitted to ORI for approval.
The supervision plan must be designed to ensure the scientific integrity of Respondents research contribution.
Respondent agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI.
Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan.
2 The requirements for Respondents supervision plan are as follows:
i. A committee of 23 senior faculty members at the institution who are familiar with Respondents field of research, but not including Respondents supervisor or collaborators, will provide oversight and guidance for a period of two 2 years from the effective date of the Agreement. The committee will review primary data from Respondents laboratory on a quarterly basis and submit a report to ORI at six 6 month intervals setting forth the committee meeting dates and Respondents compliance with appropriate research standards and confirming the integrity of Respondents research.
ii. The committee will conduct an advance review of any PHS grant applications including supplements, resubmissions, etc., manuscripts reporting PHS-funded research submitted for publication, and abstracts.
The review will include a discussion with Respondent of the primary data represented in those documents and will include a certification to ORI that the data presented in the proposed application/publication is supported by the research record.
3 Respondent agreed that for a period of two 2 years beginning on
PO 00000

Frm 00035

Fmt 4703

Sfmt 4703

46707

August 2, 2021, any institution employing him shall submit, in conjunction with each application of PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript or abstract.
4 If no supervisory plan is provided to ORI, Respondent agreed to provide certification to ORI at the conclusion of the supervision period that he has not engaged in, applied for, or had his name included on any application, proposal, or other request for PHS funds without prior notification to ORI.
5 Respondent agreed to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a consultant for a period of two 2 years, beginning on August 2, 2021.
6 As a condition of the Agreement, Respondent will request that the following papers be retracted in accordance with 42 CFR 93.407a1
and 93.411b:
Development 2015 Dec 1;14223:402637
iScience 2019 May 31;15:115
iScience 2019 Jul 26;17:22529
Respondent will copy ORI and the Research Integrity Officer at MDIBL on the correspondence.
Dated: August 16, 2021.
Wanda K. Jones, Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health.
FR Doc. 202117777 Filed 81821; 8:45 am BILLING CODE 415031P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10a of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.
The meeting will be held as a virtual meeting and is open to the public.
Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the
E:FRFM19AUN1.SGM

19AUN1